Capsaicin topical liquid - NeurogesX

Drug Profile

Capsaicin topical liquid - NeurogesX

Alternative Names: NGX-1998; NP-1998

Latest Information Update: 18 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeurogesX
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Postherpetic neuralgia

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 13 Feb 2015 Discontinued - Phase-II for Postherpetic neuralgia in USA (Topical)
  • 09 Jul 2013 Capsaicin topical liquid licensed to Acorda Therapeutics in the USA, Canada, Latin America and certain other territories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top